A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Lapatinib (Primary) ; Temozolomide (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- 19 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 19 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 09 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.